X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter Financial ResultsGlobeNewsWire • 08/03/21
X4 Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 3, 2021GlobeNewsWire • 07/22/21
X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström's Macroglobulinemia at EHA 2021GlobeNewsWire • 06/11/21
X4 Pharmaceuticals to Host Conference Call and Webcast to Present Initial Efficacy and Safety Data from EHA 2021 Poster on Phase 1b Clinical Trial of Mavorixafor in Waldenström's MacroglobulinemiaGlobeNewsWire • 05/26/21
X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström's Macroglobulinemia as Published in EHA AbstractGlobeNewsWire • 05/12/21
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/06/21
X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021GlobeNewsWire • 04/22/21
X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/07/21
X4 Pharmaceuticals Announces $55.0 Million At-the-Market Private Placement FinancingGlobeNewsWire • 03/19/21
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/04/21
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/04/21
X4 Pharmaceuticals to Participate at the Virtual B. Riley Oncology Institutional Investor ConferenceGlobeNewsWire • 01/19/21
X4 Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect ConferenceGlobeNewsWire • 01/07/21
X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM SyndromeGlobeNewsWire • 12/10/20
X4 Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare ConferenceGlobeNewsWire • 11/10/20
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/07/20
X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020GlobeNewsWire • 10/22/20
X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM SyndromeGlobeNewsWire • 10/08/20
X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison LawtonGlobeNewsWire • 10/01/20
X4 Pharmaceuticals to Participate in Three September Virtual Investor ConferencesGlobeNewsWire • 09/03/20